149 related articles for article (PubMed ID: 38195387)
61. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Casper C; Chaturvedi S; Munshi N; Wong R; Qi M; Schaffer M; Bandekar R; Hall B; van de Velde H; Vermeulen J; Reddy M; van Rhee F
Clin Cancer Res; 2015 Oct; 21(19):4294-304. PubMed ID: 26124203
[TBL] [Abstract][Full Text] [Related]
62. Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab.
Aita T; Hamaguchi S; Shimotani Y; Nakamoto Y
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33148595
[TBL] [Abstract][Full Text] [Related]
63. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R
Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942
[TBL] [Abstract][Full Text] [Related]
64. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
Fajgenbaum DC; Wu D; Goodman A; Wong R; Chadburn A; Nasta S; Srkalovic G; Mukherjee S; Leitch H; Jayanthan R; Ferrero S; Sato Y; Schey S; Dispenzieri A; Oksenhendler E; Zinzani PL; Lechowicz MJ; Hoffmann C; Pemmaraju N; Bagg A; Fossa A; Lim MS; van Rhee F;
Am J Hematol; 2020 Dec; 95(12):1553-1561. PubMed ID: 32894785
[TBL] [Abstract][Full Text] [Related]
65. Castleman's disease: from basic mechanisms to molecular therapeutics.
El-Osta HE; Kurzrock R
Oncologist; 2011; 16(4):497-511. PubMed ID: 21441298
[TBL] [Abstract][Full Text] [Related]
66. [Is there a place for interferon-alpha in the treatment strategy of multicentric Castleman's disease?].
Maloisel F; Andrès E; Campos F; Opréa C; Deslandres M; Randriamahazaka R; Kurtz JE; Koumarianou A; Dufour P
Rev Med Interne; 2000 May; 21(5):435-8. PubMed ID: 10874763
[TBL] [Abstract][Full Text] [Related]
67. Siltuximab for multicentric Castleman disease.
Liu YC; Stone K; van Rhee F
Expert Rev Hematol; 2014 Oct; 7(5):545-57. PubMed ID: 25110138
[TBL] [Abstract][Full Text] [Related]
68. A case of tocilizumab-refractory idiopathic multicentric Castleman's disease successfully treated with sirolimus.
Sumiyoshi R; Koga T; Furukawa K; Umeda M; Yamamoto K; Mori R; Kawakami A
Clin Immunol; 2021 Dec; 233():108887. PubMed ID: 34798240
[TBL] [Abstract][Full Text] [Related]
69. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease.
Fajgenbaum DC; Langan RA; Japp AS; Partridge HL; Pierson SK; Singh A; Arenas DJ; Ruth JR; Nabel CS; Stone K; Okumura M; Schwarer A; Jose FF; Hamerschlak N; Wertheim GB; Jordan MB; Cohen AD; Krymskaya V; Rubenstein A; Betts MR; Kambayashi T; van Rhee F; Uldrick TS
J Clin Invest; 2019 Aug; 129(10):4451-4463. PubMed ID: 31408438
[TBL] [Abstract][Full Text] [Related]
70. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
Mylona EE; Baraboutis IG; Lekakis LJ; Georgiou O; Papastamopoulos V; Skoutelis A
AIDS Rev; 2008; 10(1):25-35. PubMed ID: 18385778
[TBL] [Abstract][Full Text] [Related]
71. Impact of siltuximab on patient-related outcomes in multicentric Castleman's disease.
Sitenga J; Aird G; Ahmed A; Silberstein PT
Patient Relat Outcome Meas; 2018; 9():35-41. PubMed ID: 29391839
[TBL] [Abstract][Full Text] [Related]
72. Rheumatoid arthritis-like active synovitis with T-cell activation in a case of idiopathic multicentric Castleman disease: A case report.
Otsuka M; Koga T; Sumiyoshi R; Okamoto M; Endo Y; Tsuji S; Takatani A; Shimizu T; Igawa T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Daisuke N; Kawakami A
Medicine (Baltimore); 2019 May; 98(18):e15237. PubMed ID: 31045763
[TBL] [Abstract][Full Text] [Related]
73. TAFRO Syndrome: A Case of Significant Endocrinopathy in a Caucasian Patient.
Miatech JL; Patel NR; Latuso NQ; Ellipeddi PK
Cureus; 2019 Jun; 11(6):e4946. PubMed ID: 31453020
[TBL] [Abstract][Full Text] [Related]
74. Idiopathic multicentric Castleman's disease: a systematic literature review.
Liu AY; Nabel CS; Finkelman BS; Ruth JR; Kurzrock R; van Rhee F; Krymskaya VP; Kelleher D; Rubenstein AH; Fajgenbaum DC
Lancet Haematol; 2016 Apr; 3(4):e163-75. PubMed ID: 27063975
[TBL] [Abstract][Full Text] [Related]
75. Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's disease.
Terasaki Y; Ikushima S; Matsui S; Hebisawa A; Ichimura Y; Izumi S; Ujita M; Arita M; Tomii K; Komase Y; Owan I; Kawamura T; Matsuzawa Y; Murakami M; Ishimoto H; Kimura H; Bando M; Nishimoto N; Kawabata Y; Fukuda Y; Ogura T;
Histopathology; 2017 Jun; 70(7):1114-1124. PubMed ID: 28207938
[TBL] [Abstract][Full Text] [Related]
76. A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab.
Higuchi T; Nakanishi T; Takada K; Matsumoto M; Okada M; Horikoshi H; Suzuki K
J Korean Med Sci; 2010 Sep; 25(9):1364-7. PubMed ID: 20808682
[TBL] [Abstract][Full Text] [Related]
77. Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling.
Rossi JF; Chiang HC; Lu ZY; Levon K; van Rhee F; Kanhai K; Fajgenbaum DC; Klein B
Front Immunol; 2022; 13():919489. PubMed ID: 35928820
[TBL] [Abstract][Full Text] [Related]
78. An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT compliant).
Koga T; Takemori S; Hagimori N; Morimoto S; Sumiyoshi R; Shimizu T; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
Medicine (Baltimore); 2020 Dec; 99(50):e23291. PubMed ID: 33327255
[TBL] [Abstract][Full Text] [Related]
79. Membranous nephropathy associated with multicentric Castleman's disease that was successfully treated with tocilizumab: a case report and review of the literature.
Saiki R; Katayama K; Hirabayashi Y; Oda K; Fujimoto M; Murata T; Nakajima A; Dohi K
BMC Nephrol; 2021 Jun; 22(1):216. PubMed ID: 34107915
[TBL] [Abstract][Full Text] [Related]
80. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
Matsuyama M; Suzuki T; Tsuboi H; Ito S; Mamura M; Goto D; Matsumoto I; Tsutsumi A; Sumida T
Intern Med; 2007; 46(11):771-4. PubMed ID: 17541233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
